Women's Health

Study demonstrates mortality disparity among colorectal cancer patients

Delicia Honen Yard January 11, 2012

Concerted efforts to prevent or detect colorectal cancer at earlier stages in black patients could improve the worsening black-white disparities uncovered in a recent analysis.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Brachytherapy may be overused in breast cancer patients

Delicia Honen Yard January 05, 2012

Many women who underwent accelerated partial breast irradiation using brachytherapy were deemed cautionary or unsuitable for the procedure based on guidelines later issued by ASTRO.
 

Zoledronic acid continues to improve survival in premenopausal breast cancer

Delicia Honen Yard December 29, 2011

Long-term follow-up data suggest that adjuvant zoledronic acid results in highly significant disease-free and overall survival, mainly in patients with low levels of estrogen.
 

MRI may be useful as noninvasive test of breast cancer prognosis

Delicia Honen Yard December 21, 2011

MRI measures were related to prognostic tumor markers, suggesting that such imaging can provide valuable noninvasive characterization of tumor biology in people with breast cancer.
 

What You Need to Know About Breast Cancer: A Guide for Newly Diagnosed African American Women

December 19, 2011

Learning you have breast cancer doesn't stop your life. This guide helps provide more information to African American women about what to do once a cancer diagnosis is made and what the next steps should be.
 

Concurrent anastrozole/fulvestrant could be new first-line breast cancer treatment

Delicia Honen Yard December 19, 2011

Administering anastrozole (Arimidex) and fulvestrant (Faslodex) in combination rather than in sequence extended overall survival by 6 months in women with metastatic breast cancer, researchers reported at the CTRC-AACR San Antonio Breast Cancer Symposium.
 

Diabetes drug helps prevent growth of breast cancer cells

Delicia Honen Yard December 09, 2011

Metformin, a widely used agent in the treatment of type 2 diabetes, stopped a number of natural and man-made chemicals from stimulating the growth of breast cancer cells.
 

Entinostat shows which users are most likely to have delayed breast cancer progression

Delicia Honen Yard November 24, 2011

Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.
 

Bevacizumab label now warns of ovarian, osteonecrosis risks

Delicia Honen Yard October 12, 2011

The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.
 
Like to share a comment on our new site or another topic of interest to you? Click here and start typing.

ONA Newsletters
Sign up today for one of our free newsletters:
  • Issue Preview
  • Latest CE
  • Reflections
  • Editor's choice
  • New on the Web

Cancer care is expensive.
CancerCare can help.


Connect Booklets
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions